Header Logo

Connection

CHARLES F LEVENBACK to Neoplasm Recurrence, Local

Back to Details
This is a "connection" page, showing publications CHARLES F LEVENBACK has written about Neoplasm Recurrence, Local.
CHARLES F LEVENBACK
Connection Strength
0.920
Neoplasm Recurrence, Local
  1. Long-term outcomes of sentinel node mapping in vulvar cancer: A time to cheer with enthusiasm or pause and question current practice? Gynecol Oncol. 2016 Jan; 140(1):1-2.
    View in: PubMed
    Score: 0.145
  2. How important is size of sentinel lymph-node metastases in patients with vulvar cancer? Lancet Oncol. 2010 Jul; 11(7):607-8.
    View in: PubMed
    Score: 0.098
  3. How safe is sentinel lymph node biopsy in patients with vulvar cancer? J Clin Oncol. 2008 Feb 20; 26(6):828-9.
    View in: PubMed
    Score: 0.084
  4. Characteristics of recurrence in patients who underwent lymphatic mapping for vulvar cancer. Gynecol Oncol. 2004 Jan; 92(1):205-10.
    View in: PubMed
    Score: 0.063
  5. The role of radiation therapy in preventing regional recurrences of invasive squamous cell carcinoma of the vulva. Int J Radiat Oncol Biol Phys. 2003 Oct 01; 57(2):409-18.
    View in: PubMed
    Score: 0.062
  6. Groin recurrence in patients with vulvar cancer with negative nodes on superficial inguinal lymphadenectomy. Gynecol Oncol. 2003 Sep; 90(3):625-8.
    View in: PubMed
    Score: 0.062
  7. Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. JAMA Oncol. 2016 Nov 01; 2(11):1427-1433.
    View in: PubMed
    Score: 0.038
  8. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer. 2010 Aug; 20(6):936-44.
    View in: PubMed
    Score: 0.025
  9. What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies? J Chemother. 2009 Nov; 21(5):566-72.
    View in: PubMed
    Score: 0.024
  10. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol. 2009 May; 113(2):210-5.
    View in: PubMed
    Score: 0.023
  11. Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecol Oncol. 2008 Jan; 108(1):68-71.
    View in: PubMed
    Score: 0.020
  12. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol. 2007 May; 105(2):404-8.
    View in: PubMed
    Score: 0.020
  13. Time course and outcome of central recurrence after radiation therapy for carcinoma of the cervix. Int J Gynecol Cancer. 2006 May-Jun; 16(3):1106-11.
    View in: PubMed
    Score: 0.019
  14. Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. Int J Gynecol Cancer. 2006 May-Jun; 16(3):1165-71.
    View in: PubMed
    Score: 0.019
  15. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol. 2006 Apr; 101(1):126-31.
    View in: PubMed
    Score: 0.018
  16. Radical trachelectomy: is it here to stay? Gynecol Oncol. 2004 Sep; 94(3):611-3.
    View in: PubMed
    Score: 0.017
  17. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol. 2004 Apr; 93(1):27-33.
    View in: PubMed
    Score: 0.016
  18. Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. Cancer. 2001 Nov 01; 92(9):2327-33.
    View in: PubMed
    Score: 0.014
  19. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol. 2001 May; 81(2):237-41.
    View in: PubMed
    Score: 0.013
  20. Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer. Int J Gynecol Cancer. 2020 11; 30(11):1768-1774.
    View in: PubMed
    Score: 0.013
  21. Posttherapy surveillance of women with cervical cancer: an outcomes analysis. Gynecol Oncol. 2000 Aug; 78(2):187-93.
    View in: PubMed
    Score: 0.012
  22. Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary. Gynecol Oncol. 1999 Apr; 73(1):35-41.
    View in: PubMed
    Score: 0.011
  23. A phase II study of prolonged oral etoposide in advanced or recurrent carcinoma of the cervix. Gynecol Oncol. 1998 Aug; 70(2):215-8.
    View in: PubMed
    Score: 0.011
  24. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol. 1998 Mar; 16(3):1094-8.
    View in: PubMed
    Score: 0.011
  25. Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme. Gynecol Oncol. 1995 Nov; 59(2):221-5.
    View in: PubMed
    Score: 0.009
  26. Pelvic exenteration for primary and recurrent vulvar cancer. Gynecol Oncol. 1995 Aug; 58(2):202-5.
    View in: PubMed
    Score: 0.009
  27. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015 Mar 10; 33(8):930-6.
    View in: PubMed
    Score: 0.008
  28. A phase II study of carboplatin and cisplatin in advanced or recurrent squamous carcinoma of the uterine cervix. Gynecol Oncol. 1994 May; 53(2):234-8.
    View in: PubMed
    Score: 0.008
  29. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol. 1992 Sep; 46(3):317-21.
    View in: PubMed
    Score: 0.007
  30. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol. 2012 Jun; 125(3):640-5.
    View in: PubMed
    Score: 0.007
  31. The quality of cervical cancer brachytherapy implantation and the impact on local recurrence and disease-free survival in radiation therapy oncology group prospective trials 0116 and 0128. Int J Gynecol Cancer. 2012 Jan; 22(1):123-31.
    View in: PubMed
    Score: 0.007
  32. Primary malignant melanoma of the vagina. Obstet Gynecol. 2010 Dec; 116(6):1358-1365.
    View in: PubMed
    Score: 0.006
  33. Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller. Int J Gynecol Cancer. 2010 Apr; 20(3):353-7.
    View in: PubMed
    Score: 0.006
  34. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol. 2001 Sep; 82(3):420-6.
    View in: PubMed
    Score: 0.003
  35. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol. 1998 Sep; 70(3):334-8.
    View in: PubMed
    Score: 0.003
  36. Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design. J Clin Oncol. 1998 May; 16(5):1879-84.
    View in: PubMed
    Score: 0.003
  37. Pelvic exenteration for adenocarcinoma of the uterine cervix. Gynecol Oncol. 1995 Jul; 58(1):74-8.
    View in: PubMed
    Score: 0.002
  38. Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. Gynecol Oncol. 1995 May; 57(2):215-20.
    View in: PubMed
    Score: 0.002
  39. Ureteral stricture as a late complication of radiotherapy for stage IB carcinoma of the uterine cervix. Cancer. 1995 Feb 01; 75(3):836-43.
    View in: PubMed
    Score: 0.002
  40. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma. Gynecol Oncol. 1994 Oct; 55(1):47-50.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.